The Medical Advisor

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Using...

Medically & Technically Reviewed by: OneDayMD Editorial Team | Originally Published: August 9, 2026 | Updated: October 2026 Quick Answer There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), Ally Solos (from $399), or a clip-on OrCam MyEye 3 Pro (remaining dealer stock, $3,689–$4,490) read text and describe scenes aloud. The cheapest mainstream option is Meta's expanding AI-glasses lineup — Ray-Ban Meta, Meta Glasses (Adventurer/Fury), and Meta Glasses by Kylie — starting at $299, which isn't purpose-built for accessibility but has become a popular everyday alternative thanks to ...